Burns J W & Co. Inc. NY Has $7.98 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Burns J W & Co. Inc. NY cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the first quarter, Holdings Channel reports. The institutional investor owned 13,733 shares of the medical research company’s stock after selling 105 shares during the quarter. Thermo Fisher Scientific accounts for about 1.1% of Burns J W & Co. Inc. NY’s portfolio, making the stock its 26th biggest holding. Burns J W & Co. Inc. NY’s holdings in Thermo Fisher Scientific were worth $7,982,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Criterion Capital Advisors LLC boosted its holdings in Thermo Fisher Scientific by 38.6% during the first quarter. Criterion Capital Advisors LLC now owns 1,184 shares of the medical research company’s stock valued at $688,000 after purchasing an additional 330 shares in the last quarter. Trifecta Capital Advisors LLC raised its holdings in Thermo Fisher Scientific by 3.6% during the 1st quarter. Trifecta Capital Advisors LLC now owns 11,503 shares of the medical research company’s stock worth $6,686,000 after purchasing an additional 404 shares during the last quarter. Reliant Investment Management LLC boosted its stake in Thermo Fisher Scientific by 0.7% in the first quarter. Reliant Investment Management LLC now owns 12,173 shares of the medical research company’s stock valued at $7,075,000 after acquiring an additional 80 shares during the last quarter. Avity Investment Management Inc. grew its stake in shares of Thermo Fisher Scientific by 16.7% during the first quarter. Avity Investment Management Inc. now owns 73,156 shares of the medical research company’s stock worth $42,519,000 after purchasing an additional 10,481 shares during the period. Finally, WD Rutherford LLC increased its stake in shares of Thermo Fisher Scientific by 2.2% in the 1st quarter. WD Rutherford LLC now owns 7,383 shares of the medical research company’s stock valued at $4,291,000 after acquiring an additional 161 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,000 shares of company stock worth $12,532,780. 0.34% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft upped their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Jefferies Financial Group restated a “buy” rating and set a $650.00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Barclays cut their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a report on Friday. Finally, The Goldman Sachs Group increased their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $607.06.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded up $2.22 during trading hours on Friday, hitting $553.00. The company’s stock had a trading volume of 6,150,885 shares, compared to its average volume of 1,473,906. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The company has a market capitalization of $211.09 billion, a P/E ratio of 35.45, a PEG ratio of 2.57 and a beta of 0.79. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The stock has a fifty day simple moving average of $574.84 and a 200-day simple moving average of $562.59.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.